Pharmaceutical Business review

VioQuest raises $0.7 million in financing

The initial closing of the private placement consisted of the sale of 765 shares of series A convertible preferred stock for $1,000 per share. Each share of series A convertible preferred stock sold in the initial closing is convertible into shares of the company’s common stock at $0.10 per share, or 7.65 million shares of common stock in the aggregate. The purchasers also received a five-year warrant to purchase an aggregate of approximately 3.83 million shares of common stock at an exercise price of $0.13 per share.

The company reserves the right to terminate the offering of series A convertible preferred stock and warrants at any time or when subscriptions for the maximum gross offering amount of $6.9 million are received. VioQuest intends to use the proceeds of the private placement for general corporate purposes, including working capital.